Drugdocs | Xofigo

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Xofigo

Chemical Name	radium Ra 223 dichloride
Dosage Form	Injection (intravenous; 1,100 kBq/mL (30 microcurie/mL))
Drug Class	Radioactive agents
System	Male reproductive, Musculoskeletal
Company	Bayer HealthCare Pharmaceuticals Inc.
Approval Year	2013

Indication

For the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.

Last updated on 4/29/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Xofigo (radium Ra 223 dichloride) Prescribing Information	2013	Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ

Document Title	Year	Source
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases.	2016	NICE

Document Title	Year	Source
Radiopharmaceuticals for palliation of bone pain in patients with castration-resistant prostate cancer metastatic to bone: A systematic review.	2016	European Urology

Document Title	Year	Source
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.	2017	European Journal of Nuclear Medicine and Molecular Imaging